Can hospitals manufacture their own stem cells? a french trial aims to find out
NCT ID NCT07735559
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial tests whether a hospital can produce high-quality induced pluripotent stem cells (iPSCs) from blood samples taken from healthy volunteers. The goal is to create a French hospital-based platform that can generate clinical-grade stem cells for future regenerative medicine applications. Blood samples from four healthy adults will be used to create iPSC lines, which will then be checked for quality and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blood collection for induced pluripotent stem cell (iPSC) generation
- What this could lead to
- If successful, this could establish a hospital-based platform to produce clinical-grade stem cells for future regenerative therapies.
- What could go wrong
- This is a very early feasibility study with only 6 participants, focused on manufacturing rather than treating disease. The stem cells may not meet quality standards.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDUCED PLURIPOTENT STEM CELLS (IPSC) PRODUCTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Montpellier
Montpellier, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.